BND-35
BND-35 is a human monoclonal antibody (mAb) targeting LILRB4/ILT3/CD85k. BND-35 blocks the interaction of ILT3 with APOE and fibronectin, enhances the pro-inflammatory activity of various myeloid cells, and reverses ILT3-mediated immunosuppression of T cells by various suppressive myeloid cells. BND-35 has anti-tumor activity in the hILT3 transgenic mouse tumor model[1].
Product Specifications
UNSPSC
12352203
Target
Transmembrane Glycoprotein
Related Pathways
Immunology/Inflammation
Applications
Cancer-programmed cell death
Field of Research
Cancer
References & Citations
[1]Peretz T, et al. BND-35, a novel anti-ILT3 antibody for remodulation of the tumor microenvironment[J]. Cancer Research, 2024, 84 (6_Supplement) : 3920-3920.
Shipping Conditions
Room temperature
Scientific Category
Inhibitory Antibodies
Clinical Information
No Development Reported
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
031562-AP 200 µL
ACSM1, NT (ACSM1, BUCS1, LAE, MACS1, Acyl-coenzyme A synthetase ACSM1, mitochondrial, Acyl-CoA synthetase medium-chain family member 1, Butyrate-CoA ligase 1, Butyryl-coenzyme A synthetase 1, Lipoate-activating enzyme, Middle-chain acyl-CoA synthetase 1) (AP) discontinued
Ask
View Details 
